NES and cholangiocarcinoma: Nestin can potentially further aid in the future selection of patients most likely to benefit from LT as Calderaro et al. have shown that patients who underwent transplantation and had cHCC-CCA and low levels of nestin (≤30% neoplastic cells with positive staining) can achieve a favourable 5-year OS of ∼70%.16